Ignite Creation Date:
2025-12-24 @ 9:32 PM
Ignite Modification Date:
2025-12-25 @ 7:17 PM
Study NCT ID:
NCT05767632
Status:
COMPLETED
Last Update Posted:
2023-03-14
First Post:
2023-02-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
Sponsor:
Genuine Research Center, Egypt
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-30
Start Date Type:
ACTUAL
Primary Completion Date:
2022-07-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-25
Completion Date Type:
ACTUAL
First Submit Date:
2023-02-21
First Submit QC Date:
None
Study First Post Date:
2023-03-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-02
Last Update Post Date:
2023-03-14
Last Update Post Date Type:
ACTUAL